Comparison of Pulmonary Function Decline in Steroid-Treated and Steroid-Naive Patients with Duchenne Muscular Dystrophy

被引:12
|
作者
Sawnani, Hemant [1 ,2 ]
Horn, Paul S. [2 ,3 ]
Wong, Brenda [2 ,3 ]
Darmahkasih, Andrew [4 ]
Rybalsky, Irina [2 ,3 ]
Shellenbarger, Karen C. [3 ]
Tian, Cuixia [2 ,3 ]
Rutter, Meilan M. [2 ,5 ]
Simakajornboon, Narong [1 ,2 ]
Amin, Raouf [1 ,2 ]
Gurbani, Neepa [1 ,2 ]
Pascoe, John [1 ,2 ]
Burrows, Carolyn [1 ]
Khirani, Sonia [6 ,7 ]
Amaddeo, Alessandro [6 ]
Fauroux, Brigitte [6 ]
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Pulm Med, MLC 7041,3333 Burnet Ave, Cincinnati, OH 45229 USA
[2] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA
[4] Wayne State Univ, Sch Med, Detroit, MI USA
[5] Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA
[6] Necker Univ Hosp, Pediat Noninvas Ventilat & Sleep Unit, Paris, France
[7] ASV Sante, Gennevilliers, France
来源
JOURNAL OF PEDIATRICS | 2019年 / 210卷
关键词
RESPIRATORY-FUNCTION; PREDNISONE THERAPY; HEIGHT; TRIAL; SURVIVAL; IMPACT;
D O I
10.1016/j.jpeds.2019.02.037
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To describe and compare the lung function decline in patients with Duchenne muscular dystrophy on glucocorticoid therapy in contrast with glucocorticoid-naive patients, and to define the deciles of pulmonary decline in glucocorticoid-treated patients. Study design This retrospective study examined lung function of patients with Duchenne muscular dystrophy over 6 years of age followed between 2001 and 2015 at 2 centers-glucocorticoid-treated patients in Cincinnati, Ohio, and glucocorticoid-naive patients in Paris, France. Forced vital capacity (FVC, FVC%), forced expiratory volume in 1 second, maximal inspiratory pressure, maximal expiratory pressure, and peak expiratory flow data were analyzed. Only FVC data were available for the French cohort. Results There were 170 glucocorticoid-treated patients (92%), 5 patients (2.7%) with past glucocorticoid use, and 50 French glucocorticoid-naIve patients. The peak absolute FVC was higher and was achieved at earlier ages in glucocorticoid-treated compared with glucocorticoid-naive patients (peak FVC, 2.4 +/- 0.6 L vs 1.9 +/- 0.7 L; P < .0001; ages 13.5 +/- 3.0 years vs 14.3 +/- 2.8 years; P = .03). The peak FVC% was also higher and was achieved at earlier ages in glucocorticoid-treated patients (peak FVC%, 105.1 +/- 25.1% vs 56 +/- 20.9%; P < .0001; ages 11.9 +/- 2.9 years vs 13.6 +/- 3.2 years; P = .002). Rates of decline for both groups varied with age. Maximal rates of decline were 5.0 +/- 0.26% per year (12-20 years) for glucocorticoid-treated and 5.1 +/- 0.39% per year for gluco-corticoid-naive patients (11-20 years; P = .2). Deciles of FVC% decline in glucocorticoid-treated patients show that patients experience accelerated decline at variable ages. Conclusions These data describe nonlinear rates of decline of pulmonary function in patients with Duchenne muscular dystrophy, with improved function in glucocorticoid-treated patients. FVC% deciles may be a useful tool for clinical and research use.
引用
收藏
页码:194 / +
页数:9
相关论文
共 50 条
  • [31] Pulmonary function characteristics of boys with Duchenne Muscular Dystrophy by age groups, ambulatory status and steroid use
    Abresch, R. T.
    McDonald, C. M.
    Henricson, E. K.
    Gustavo, N.
    Hu, F.
    Duong, T.
    Joyce, N.
    Mah, J.
    NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 801 - 802
  • [32] Neuropeptide degradation in naive and steroid-treated allergic saliva
    Albo, F
    Antonangeli, R
    Cavazza, A
    Marini, M
    Roda, LG
    Rossi, P
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (9-10) : 1777 - 1788
  • [33] The Quest for the Prediction of Steroid Responsiveness in Duchenne Muscular Dystrophy
    Suthar, Renu
    Sahu, Jitendra Kumar
    INDIAN JOURNAL OF PEDIATRICS, 2020, 87 (09): : 682 - 683
  • [34] TRENDS IN STEROID THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY IN JAPAN
    Takeuchi, Fumi
    Komaki, Hirofumi
    Nakamura, Harumasa
    Yonemoto, Naohiro
    Kashiwabara, Kousuke
    Kimura, En
    Takeda, ShiN'Ichi
    MUSCLE & NERVE, 2016, 54 (04) : 673 - 680
  • [35] Trends of steroid therapy for Duchenne muscular dystrophy in Japan
    Takeuchi, F.
    Komaki, H.
    Nakamura, H.
    Yonemoto, N.
    Kashiwabara, K.
    Kimura, E.
    Takeda, S.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S199 - S199
  • [36] The Quest for the Prediction of Steroid Responsiveness in Duchenne Muscular Dystrophy
    Renu Suthar
    Jitendra Kumar Sahu
    The Indian Journal of Pediatrics, 2020, 87 : 682 - 683
  • [37] Platelet Function and Activation in Patients with Immune Thrombocytopenia Treated with Eltrombopag: Comparison with Steroid-Treated and Untreated Patients
    Haselboeck, Johanna
    Kaider, Alexandra
    Pabinger, Ingrid
    Panzer, Simon
    BLOOD, 2011, 118 (21) : 1410 - 1410
  • [38] Exhaled NO, body mass index and pulmonary function tests in patients with steroid-naive asthma and allergic rhinitis
    Sergeeva, G.
    Leshenkova, E.
    Rebrova, S.
    Znakhurenko, A.
    Kozireva, L.
    Emelyanov, A.
    ALLERGY, 2014, 69 : 148 - 149
  • [39] CHANGE IN PULMONARY FUNCTION IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY
    Lim, D. J.
    Goh, D. Y.
    Tapawan, S. J.
    Tay, S.
    Ramamurthy, M. B.
    Lim, M. T.
    PEDIATRIC PULMONOLOGY, 2016, 51 : S78 - S78
  • [40] Characterization of pulmonary function in patients with Duchenne muscular dystrophy
    Finkel, R. S.
    Rummey, C.
    Mayer, O. H.
    Benton, M. J.
    Glanzman, A. M.
    Flickinger, J.
    Leinonen, M.
    Meier, T.
    NEUROMUSCULAR DISORDERS, 2010, 20 (9-10) : 669 - 669